Results from Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma

Get the results from the AMBASSADOR study presented by Dr. Andrea Apolo from the National Cancer Institute at ASCO GU 2024 in this MEDtalk. The study is a multi-center phase III trial investigating the efficacy of adjuvant pembrolizumab versus observation in patients with muscle-invasive urothelial carcinoma. Notably, disease-free survival extended to a median of 29 months compared to 14 months in the control group. Despite the overall survival data still maturing, this study paves the way for pembrolizumab as a potential treatment option for patients post-radical surgery and elaborates on the prognostic role of PD-L1 status and how it shapes treatment decisions within this patient demographic.